Dulaglutide Market Report 2025

This Dulaglutide market report provides a comprehensive analysis of the market’s characteristics, size, and growth, including segmentation, regional and country-level breakdowns, competitive landscape, market shares, trends, and strategies. It also tracks historical and forecasted market growth across various geographies.

The dulaglutide market size has grown strongly in recent years. It will grow from $4.17 billion in 2024 to $4.51 billion in 2025 at a compound annual growth rate (CAGR) of 8.2%. The growth in the historic period can be attributed to the increasing prevalence of type 2 diabetes, increasing utilization, increasing research and development investments, increased focus on chronic diseases, and growth in personalized medicine.

The dulaglutide market size is expected to see strong growth in the next few years. It will grow to $6.1 billion in 2029 at a compound annual growth rate (CAGR) of 7.8%. The growth in the forecast period can be attributed to increasing clinical trials, rising obesity rates, rising aging population, growing telemedicine services, growing endocrinology clinics, and growing use of electronic health records. Major trends in the forecast period include technological advancements, personalized medicine, telemedicine, digital health platforms, and mobile health apps.

The rising prevalence of type 2 diabetes is expected to drive the growth of the dulaglutide market in the coming years. Type 2 diabetes is a chronic condition where the body becomes resistant to insulin or doesn't produce enough, leading to high blood sugar levels. The growing incidence of type 2 diabetes is attributed to increasing obesity rates, poor dietary habits, and sedentary lifestyles. Dulaglutide helps manage type 2 diabetes by boosting insulin secretion and lowering glucagon levels in response to food intake, which helps reduce blood sugar levels. For example, in April 2023, a report from The British Diabetic Association, a UK-based diabetes charity, revealed that 4.3 million people in the UK have diabetes, with over 2.4 million at high risk of developing type 2 diabetes. Additionally, registration numbers for 2021-22 increased by 148,951. Therefore, the rising prevalence of type 2 diabetes is fueling the growth of the dulaglutide market.

Leading companies in the dulaglutide market are actively developing innovative products, including anti-diabetic drugs, to meet the rising demand for effective diabetes mellitus management. Anti-diabetic medications regulate blood sugar levels by enhancing insulin sensitivity, stimulating insulin production, or slowing glucose absorption from the digestive tract. For instance, in January 2024, Glenmark Pharmaceuticals Limited launched the first biosimilar of the anti-diabetic drug Liraglutide in India under the brand name Lirafit. This strategic move marks Glenmark's entry into the biosimilar market for anti-diabetic drugs, offering patients a more affordable treatment option while maintaining comparable efficacy and safety profiles to the original drug, meeting stringent regulatory standards.

In August 2023, Lupin Limited acquired two diabetic brands from Boehringer Ingelheim for €26 million ($28 million). This acquisition strengthens Lupin's position in the diabetes care market by expanding its product portfolio and market presence in diabetes management. Boehringer Ingelheim, a Germany-based company, is involved in the development and marketing of dulaglutide, a medication used to treat type 2 diabetes.

Major companies operating in the dulaglutide market are Merck And Co. Inc., AstraZeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Cipla Limited, Intas Pharmaceuticals Limited, Biocon Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Glenmark Pharmaceuticals Limited, Insulet Corporation, Nicholas Piramal India Limited, IPCA Laboratories Limited, Alembic Pharmaceuticals Limited, Ypsomed Holding AG, Wockhardt Limited, MannKind Corporation, Bioton S.A., Midas Pharma GmbH, Senova Technology Co. Ltd., Enomark.

North America was the largest region in the dulaglutide market in 2024. The regions covered in the dulaglutide market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the dulaglutide market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Dulaglutide is a drug used to control blood sugar levels in people with type 2 diabetes. It belongs to the class of glucagon-like peptide-1 (GLP-1) receptor agonists, which imitate the effects of the natural hormone GLP-1. Dulaglutide is given through a subcutaneous injection, usually once a week.

Dulaglutide is available primarily in syringe pens and multi-dose bottles. The syringe pen is a device for injecting medications such as dulaglutide. It integrates the medication and needle into a single, user-friendly instrument. This allows patients to adjust the dosage as needed, offering precision and convenience. The product is utilized in medical insurance, pharmaceuticals, and clinical research, and is available through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The dulaglutide market research report is one of a series of new reports that provides dulaglutide market statistics, including dulaglutide industry global market size, regional shares, competitors with a dulaglutide market share, detailed dulaglutide market segments, market trends, and opportunities, and any further data you may need to thrive in the dulaglutide industry. This dulaglutide research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dulaglutide market consists of sales of blood glucose monitors, needles, and injection pens. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.